STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 29, 2020	$ 131,449	$ 123,373,793	$ (123,657,829)	$ (152,587)
Balance (in shares) at Feb. 29, 2020	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		394,268		394,268
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		916,474		916,474
Net loss			(1,203,998)	(1,203,998)
Balance at Feb. 28, 2021	$ 131,449	124,684,535	(124,861,827)	(45,843)
Balance (in shares) at Feb. 28, 2021	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		328,418		328,418
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		695,287		695,287
Net loss			(976,656)	(976,656)
Balance at Feb. 28, 2022	$ 131,449	$ 125,708,240	$ (125,838,483)	$ 1,206
Balance (in shares) at Feb. 28, 2022	131,448,444